| Code | CSB-RA001707MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to Nesvacumab, designed to specifically target angiopoietin-2 (ANGPT2), a secreted glycoprotein that plays a critical role in vascular remodeling and angiogenesis. ANGPT2 functions as a context-dependent antagonist of the TIE2 receptor, destabilizing blood vessels and promoting vascular permeability and sprouting in the presence of pro-angiogenic factors like VEGF. Dysregulated ANGPT2 expression is implicated in various pathological conditions, including tumor angiogenesis, metastatic progression, diabetic retinopathy, and inflammatory vascular disorders, making it an important therapeutic target in oncology and ophthalmology research.
Nesvacumab, the reference antibody, was developed as an investigational anti-angiogenic agent and has been evaluated in clinical trials for advanced solid tumors, often in combination with anti-VEGF therapies. This biosimilar antibody provides researchers with a valuable tool for investigating ANGPT2-mediated signaling pathways, studying tumor microenvironment dynamics, exploring vascular biology mechanisms, and evaluating potential therapeutic strategies targeting pathological angiogenesis in preclinical models.
There are currently no reviews for this product.